Chemomab Therapeutics (CMMB) Research & Development (2017 - 2025)

Chemomab Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Research & Development fell 54.67% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (down 48.5% YoY) and the FY2025 annual result came in at $5.8 million, down 48.5% from the prior year.
• Research & Development was $1.1 million for Q4 2025 at Chemomab Therapeutics, up from $960000.0 in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q1 2023 and bottomed at $960000.0 in Q3 2025.
• A 5-year average of $2.9 million and a median of $2.8 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 264.69% — and 2025, when it slumped 66.15%.
• Chemomab Therapeutics' Research & Development stood at $2.4 million in 2021, then jumped by 147.38% to $5.9 million in 2022, then sank by 47.46% to $3.1 million in 2023, then decreased by 22.15% to $2.4 million in 2024, then tumbled by 54.67% to $1.1 million in 2025.
• Business Quant data shows CMMB's Research & Development at $1.1 million in Q4 2025, $960000.0 in Q3 2025, and $1.3 million in Q2 2025.